SynthesisPloS one2021
Low vs standardized dose anticoagulation regimens for extracorporeal membrane oxygenation: A meta-analysis.
Synthesis in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Combined circuit-directed (pre-oxygenator) nafamostat and low-dose systemic unfractionated heparin anticoagulation in ecmo patients with high bleeding risk: A case series and safety evaluation.Journal of thrombosis and thrombolysis · 2026Article
- A best evidence summary of anticoagulation management for extracorporeal membrane oxygenation in adults.Medicine · 2026Article
- Extracorporeal Membrane Oxygenation Haemoperfusion for Leptospirosis Pulmonary Hemorrhagic Disease: Report of 1 Case.Respirology case reports · 2026Article
- Mortality and complications in low-dose vs standard-dose unfractionated heparin anticoagulation for extracorporeal membrane oxygenation: a systematic review and meta-analysis.Research and practice in thrombosis and haemostasis · 2026Article
- Challenges of ECMO use for severe trauma: a narrative review.Hereditas · 2025Review
- Anticoagulation in ECMO: Target Values to Reduce Hemorrhagic Complications in Adults. A Retrospective Cohort Study.ASAIO journal (American Society for Artificial Internal Organs : 1992) · 2025Article
- Analysis of the feasibility of a low-anticoagulation strategy in patients undergoing post-cardiotomy extracorporeal membrane oxygenation: a retrospective cohort study.BMC anesthesiology · 2025Article
- Article
- A safety comparison of heparin and argatroban anticoagulation in veno-venous extracorporeal membrane oxygenation with a focus on bleeding.Transfusion medicine (Oxford, England) · 2025Observational
- Successful management of severe pulmonary form of leptospirosis with VV-ECMO, prone ventilation, and bronchoalveolar lavage: two case reports.Frontiers in medicine · 2025Article
- Different low activated clotting time target anticoagulation protocols for patients during extracorporeal membrane oxygenation management: a retrospective cohort study.Frontiers in medicine · 2025Article
- Prognostic accuracy of oxygen debt for mortality in patients undergoing venoarterial extracorporeal membrane oxygenation therapy: a retrospective cohort study.Frontiers in medicine · 2025Article
- Severe Traumatic Brain Injury and Pulmonary Embolism: Risks, Prevention, Diagnosis and Management.Journal of clinical medicine · 2024Review
- Anticoagulation during extracorporeal membrane oxygenation.The Cochrane database of systematic reviews · 2024Article
- Extracorporeal Membrane Oxygenation (ECMO)-Associated Coagulopathy in Adults.Diagnostics (Basel, Switzerland) · 2023Review
- Safety of low-dose anticoagulation in extracorporeal membrane oxygenation using the Permanent Life Support System: a retrospective observational study.Journal of Yeungnam medical science · 2023Article
- Sustaining Life versus Altering Life-Saving Drugs: Insights to Explain the Paradoxical Effect of Extracorporeal Membrane Oxygenation on Drugs.Journal of clinical medicine · 2023Review
- Neurologic Complications of Patients With COVID-19 Requiring Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis.Critical care explorations · 2023Review
- Current status of ECMO for massive pulmonary embolism.Frontiers in cardiovascular medicine · 2023Review
- Anticoagulation Management in High Bleeding-Risk ECMO in Adults.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo compare the safety and efficacy of low-dose anticoagulation (LA) with that of standardized dose anticoagulation (SA) for patients supported with extracorporeal membrane oxygenation (ECMO).
methodsPubMed, MEDLINE, the Cochrane Library, and Web of Science were screened for original articles. Screening was performed using predefined search terms to identify cohort studies reporting the comparison of LA with SA in patients supported with ECMO from Nov 1990 to Jun 2020. The effect size was determined by the odds ratio (OR) with the 95% confidence interval (CI).
resultsAn analysis of 7 studies including a total of 553 patients was performed. LA (Low-heparin group) was administered to 255 patients, whereas the other 298 patients received SA (Full-heparin group). The incidence of gastrointestinal tract hemorrhage (OR 0.36, 95% CI 0.20-0.64) and surgical site hemorrhage (OR 0.43, 95% CI 0.20-0.94) were significantly lower in patients who underwent LA compared with that in those who underwent SA. The rates of hospital mortality (OR 0.81, 95% CI 0.42-1.56), successfully weaning off of ECMO (OR 0.80, 95% CI 0.30-2.14), pulmonary embolism (OR 0.79, 95% CI 0.24-2.65), intracardiac thrombus (OR 0.34, 95% CI 0.09-1.30), intracranial hemorrhage (OR 0.62, 95% CI 0.22-1.74), and pulmonary hemorrhage (OR 0.77, 95% CI 0.30-1.93) were similar between the two groups.
conclusionsThis meta-analysis confirms that LA is a feasible and safe anticoagulation strategy in patients supported by ECMO. Future studies should focus on the long-term benefits of LA compared with SA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.